Journey Strategic Wealth LLC Purchases 20,630 Shares of Pfizer Inc. $PFE

Journey Strategic Wealth LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 72.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 49,185 shares of the biopharmaceutical company’s stock after purchasing an additional 20,630 shares during the period. Journey Strategic Wealth LLC’s holdings in Pfizer were worth $1,192,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Pfizer by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after acquiring an additional 10,198,330 shares during the period. Geode Capital Management LLC grew its stake in shares of Pfizer by 1.4% in the second quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock worth $3,080,552,000 after purchasing an additional 1,820,634 shares during the last quarter. Northern Trust Corp increased its holdings in Pfizer by 6.8% in the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock valued at $1,579,340,000 after purchasing an additional 3,943,397 shares during the period. Amundi raised its position in Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in Pfizer by 3.7% during the 2nd quarter. Legal & General Group Plc now owns 38,444,771 shares of the biopharmaceutical company’s stock worth $931,901,000 after buying an additional 1,384,227 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock opened at $25.02 on Friday. The firm has a 50 day moving average of $24.84 and a 200-day moving average of $24.47. The company has a market cap of $142.26 billion, a price-to-earnings ratio of 13.31, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is 100.00%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PFE. Bank of America increased their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Scotiabank initiated coverage on shares of Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price for the company. Morgan Stanley lowered their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $28.28.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.